CDD Invention, Sulfanegen, Being Marketed for Anti-Cyanide Therapy (Profs. Vince, Nagasawa, and Patterson)

Thursday, February 9, 2012

CDD Invention, Sulfanegen, Being Marketed for Anti-Cyanide TherapyBased on research conducted at the Center for Drug Design (CDD), Sulfanegen, a treatment for cyanide poisoning, will be developed and marketed. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.

Sulfanegen was invented by Drs. Steve Patterson; Robert Vince, director of CDD; and Herbert Nagasawa, adjunct at CDD. The research was funded by the CDD and the NIH CounterACT (Counter-measures Against Chemical Threats) program, an effort involving a number of NIH institutes that enhances the nation’s diagnostic and treatment response capabilities during a chemical emergency.

Read More